Probiotic potential of Lacticaseibacillus rhamnosus VHProbi M15 on sucralfate-induced constipation in mice

The main objective of this study was to investigate the potential probiotic properties of Lacticaseibacillus rhamnosus VHProbi®M15 (M15). This study examined the effects of M15 on sucralfate-induced constipation in a mouse model. The BALB/c mice were randomly divided into four groups: the normal group (NOR) was without any treatment, while the constipation (CON), phenolphthalein (PHE), and probiotic (PRO) treatment groups were fed with sucralfate until the appearance of constipation symptoms. Afterward, the NOR and CON groups were given 1 ml saline orally every day until the end of the experiment; the PHE and PRO groups were given phenolphthalein or M15 suspension in 1 ml orally, respectively. Compared with the CON group, the fecal water content and intestinal peristalsis improved in the PRO group. Here, intake of M15 effectively attenuated sucralfate-induced constipation, recuperated colonic epithelial integrity, and increased serum levels of gastrointestinal excitatory neurotransmitters (motilin, gastrin, substance P). Analysis of the intestinal microbiota of mice by 16S rRNA metagenomic revealed an increase in the relative abundance of Bacteroides and a decrease in Sclerotinia, Verrucosa and Proteus in the PRO group. Compared with the CON group, the constipation-induced intestinal microecological changes were partially recovered in the PHE and PRO groups. These results demonstrate that M15 enhanced gastrointestinal transit and alleviated in mice with sucralfate-induced constipation.

Constipation, a common gastrointestinal symptom, affects all ages of humans and may lead to gastrointestinal diseases such as colorectal cancer and irritable bowel syndrome 1 .Standard treatments, such as laxatives, help achieve normal defecation habits, that is, pain-free soft defecation.However, laxatives have several side effects, such as arrhythmia, abdominal cramps, and myocardial infarction 2 .Therefore, it is necessary to treat chronic constipation more gently and effectively.
Probiotics have great prospects as a treatment option for chronic constipation.There are several possible biological mechanisms by which probiotics relieve constipation, including restoring balance after intestinal disorders, altering intestinal sensations and gut microbe metabolites, and regulating the lumen environment 3 .Li et al. 1 showed that probiotics can increase the amount of short-chain fatty acids (SCFAs), which affects colon peristalsis relieving constipation.Chen et al. 4 showed that probiotics produced SCFAs reduce intestinal pH and colon transit time.In addition, probiotics-induced changes in intestinal flora can also alleviate constipation symptoms 5 .Presently, lactic acid bacteria (LAB) are one of the most popular probiotics that have been in use for a long time and have no reported risks in humans.Therefore, the development of new LAB probiotic strains is a safe and promising path for the treatment of constipation.
M15, a potential LAB probiotic strain, was identified in the breast milk of those who did not take probiotic products within 6 months.M15 exhibited excellent tolerance against simulated gastric juice and bile salts.This study examined the effects of M15 on constipation and intestinal microflora in mice.We hypothesized that M15 supplementation can enhance intestinal motility and inhibit constipation symptoms.Accordingly, we extracted mice fecal DNA for 16S rRNA high-throughput sequencing and analyzed the structural change in intestinal flora after M15 treatment.Redundancy analysis (RDA) revealed that mice intestinal flora was significantly changed in different treatment groups.Our results highlight the positive effect of M15 on constipation through changes in intestinal motility and flora in mice.

M15 increased intestinal transit rate (GI) and peristalsis in constipated mice
The transportation length of the small intestine is one of the indices to measure the total transportation capacity of the small intestine 8 .The GI transit rate was measured to evaluate the effect of M15 on intestinal peristalsis.Compared with the NOR group, the GI transit rate of the CON group was significantly lower (p < 0.05, Fig. 2A), indicating the establishment of the constipation model.However, M15 supplementation significantly increased the GI transit rate in the PRO group (p < 0.05), almost to the normal level but slightly lower than the PHE group.In all, M15 promoted intestinal peristalsis in constipated mice.Compare with the NOR group, the intestinal transmission length was significantly shorter in other groups (p < 0.05, Fig. 2B) as tested by charcoal movement.However, the intestinal transport length of the PRO group was longer than the CON group.According to the intestinal anatomy, the peristalsis distance was the shortest in the CON group, followed by the PHE group, PRO group, and then the NOR group.

M15 improved fecal SCFAs levels
As shown in Table 1, The contents of acetic, propionic, butyric, and total organic acids in the feces of all four groups were relatively stable before the establishment of the constipation model by sucralfate (the first 14 days).There was no significant difference in SCFAs concentration between the CON and NOR mice on the 7th and 14th days.However, on the 21st day, the contents of acetic and total acids significantly decreased in CON mice than those in NOR mice (p < 0.001); the acetic acid amounts increased after treatment with M15 in PRO mice (p < 0.05) and became comparable to NOR mice but slightly lower than PHE mice.Likewise, the content of total organic acid also increased (p < 0.05), which was similar to that in NOR and PHE mice.

M15 affects serum levels of gastrointestinal regulatory-related peptides
The effects of M15 on constipation were further evaluated by measurement of serum parameters in the experimental mice, including MTL, Gas, SP, ET-1, SS, and VIP.As shown in Fig. 3, compared with the NOR group, the serum levels of MTL, GAS, and SP were significantly decreased (P < 0.01), and that of SS, ET-1, and VIP were significantly increased in the CON group (P < 0.01).However, the trend reversed in the PRO and PHE groups, i.e., MTL, GAS, and SP increased (P < 0.01), while SS, ET-1, and VIP decreased compared with the CON group (P < 0.01).In all, these results thereby indicated that M15 could stimulate the release of gastrointestinal regulatory-related excitatory neurotransmitters.www.nature.com/scientificreports/

M15 supplementation alleviated constipation-induced pathological implications of the small intestine
The effect of M15 on constipation-induced changes in the distal colon tissue of mice is shown in Fig. 4. The NOR group showed the normal morphological characteristics of epithelial cells after H&E staining of colon tissues; it exhibited well-defined crypts and goblet cells, and the thick layers of colon tissues.In the CON group, intestinal villi were severely broken, the intestinal wall was damaged and the infiltration of inflammatory cells was prevalent.However, the PRO group showed serious signs of recovery; the rupture of intestinal villi and the injury of the intestinal lining were alleviated, intestinal villi became slightly edematous and only a small amount of intestinal villi remained necrotic.This data showed that both M15 and polyphenols effectively inhibited intestinal villi destruction, mucosal ulcer, and colon inflammation.

M15 restored intestinal flora in constipated mice
The changes in the intestinal flora in mice were mainly detected by the changes in the bacteria in their feces.How do mouse intestinal flora change after constipation, and after supplementation with M15?To explore the effect of M15 on the intestinal microbiome composition of mice, 16S rRNA sequencing was performed by Illumina Hiseq.In this study, 24 mouse feces samples were collected.In total, 2,350,178 effective sequences of 16S rDNA with an average length of 252 bp were generated.The representative sequences of all sequences were clustered based on 97% sequence similarity.The Sobs and Shannon indices were used to reflect the richness and diversity of microbial communities in different samples, respectively.Compared with the NOR group, the Sobs and Shannon indices were significantly decreased in the CON group (Fig. 5; P < 0.05), indicating that constipation decreased the richness and diversity of microbial species.However, compared with the CON group, the Sobs index improved in PHE and PRO groups (PRO group, P < 0.01; PHE group, P < 0.05); the Shannon index increased too but the difference was not significant.These results showed that M15 supplementation improved species richness and diversity in CON mice.
When the single operational taxa (OTUs) were analyzed at the phylum level (Fig. 6), we found that the mice intestinal flora was mainly composed of Bacteroides, Firmicutes, Verrucomicrobia, Proteobacteria, and Actinomycetes.Notably.Compared with the NOR group, we found that Firmicutes, Verrucomicrobia, Proteobacteria, and Actinomycetes were increased but Bacteroides were decreased in the feces of CON mice.Firmicutes and Proteobacteria were significantly decreased, while Verrucosa was significantly increased in the PHE group feces.
In the PRO group samples, Bacteroides increased, while Firmicutes, Verrucosa, and Proteobacteria decreased; the phylum species composition of the PRO group became similar to NOR mice.The relative abundance of Verrucomicrobia was significantly reduced in the PRO group compared to the PHE group, while the relative levels of Bacteroides were increased.The abundance ratio of firmicutes to Bacteroidetes reappeared in mice after PRO administration.This indicated that M15 supplementation in CON mice restored normal flora composition at the phylum level as in NOR mice.At the genus level, compared with the NOR group, the abundance of Lactobacillus was significantly decreased while that of Akkemansia and Streptococcus was increased in the CON group (Fig. 7).In the PHE group, Lactobacilli were decreased while Akkemansia and Alloprevotella were increased significantly.Compared with the CON group, Lactobacillus, and Alloprevotella were increased, while Akkemansia and Streptococcus were decreased in the PRO group.Compared with the PHE group, Lactobacillus was significantly increased and Akkemansia was significantly decreased in the PRO group.www.nature.com/scientificreports/ The β diversity analysis of fecal samples is shown in Fig. 8. PCoA coordinate analysis revealed that the mice intestinal flora structure differed between the NOR and CON groups, and PHE and PRO groups, while NOR and PRO groups showed some similarities.CON and NOR groups were significantly separated, indicating that intestinal microbiota composition had changed in the CON group.PRO and NOR groups were closely clustered, suggesting that PRO treatment could restore the composition of intestinal microbiota to a certain extent.Overall, the above results indicated that M15 somewhat restored normal intestinal flora in constipated mice.

Discussion
Probiotics are living microorganisms that can positively impact human health when ingested in sufficient quantities.Gut microbiota plays an important role in gastrointestinal homeostasis and functions.With the advancement of science and technology, food has become more refined, but sleep and exercise have been greatly reduced.These social changes have increased constipation symptoms such as prolonged defecation and hard stool in people.At present, Lactobacillus, Bifidobacterium, Bacillus, and Streptococcus have been used as probiotics in humans, which play a positive role in many aspects of the human body.However, most probiotics lose activity during digestion.Survival in gastric and intestinal juices is the basic requirement for probiotics to colonize the gastrointestinal tract, and then play a role in the target site.We screened the M15 strain from fresh breast milk, which showed good survival in artificial gastric (99.8%) juice, which means M15 can survive in a harsh gastrointestinal environment.In addition, the Caco-2 cell line isolated from human colon adenocarcinoma was used as an in vitro model of the intestinal epithelium to study M15 adhesion to the intestine.The number of M15 adhered to Caco-2 cells was counted by microscopy counting; we found a large number of M15 adhered to the cell surface.M15 showed good adhesion properties indicating that it is well capable of colonizing the colon, a prerequisite of a good probiotic.The high survival percentage in the gastrointestinal setting is M15's greatest advantage as a probiotic to relieve constipation symptoms.M15 is a strain of Lactobacillus rhamnosus, which is different from B. animalis VHProbi YB11 9 published by CUI.M15 has better growth ability and gastrointestinal fluid tolerance than YB11, and has a more significant effect on constipation.In addition, M15 has more potential for application, as it provides in-depth study of the effects of probiotics on the improvement of intestinal flora.
Sucralfate is mainly used for gastric mucosal injury in clinical practice.Also, it can induce constipation in mice by inhibiting intestinal motility and increasing intestinal water absorption 10 .In this study, the mice constipation model was established by oral administration of sucralfate.Fecal water content and intestinal transit ratio are commonly used to evaluate constipation.The slower the intestine peristalsis, the longer feces remain in the intestine.This leads to more water absorption in the intestine, leaving less water content in feces.Meanwhile, excessively dry feces may also cause damage to the intestinal lining villi 11 .On the contrary, good intestinal peristalsis improves the fecal water content, relieving constipation symptoms.Compared with the NOR group, the CON group showed significantly decreased water content, decreased intestinal passage rate, and severe intestinal lining damage, while the PRO and PHE groups showed improved fecal water content and intestinal passage rate and reduced intestinal villi damage compared with the CON group.These results suggested that M15 can relieve constipation by promoting fecal moisture content and peristalsis.
SCFAs are metabolites of intestinal bacteria and are closely related to the peristaltic efficiency of the intestine 12 .SCFAs can stimulate intestinal peristalsis and increase osmotic pressure, thus increasing the water content in the intestine 13 .Low intestinal pH promotes the competitive binding of SCFAs to receptors in intestinal epithelial www.nature.com/scientificreports/cells or mucosa, improving intestinal flora in patients with constipation 14 .A previous study 15 demonstrated that probiotics can improve defecation by increasing the colon content of SCFAs and in turn softening fecal stools in constipation model animals.Li & Nie 1 also showed that SCFAs are essential for the integrity of the colonic epithelium: they stimulate the proliferation of epithelial colonic cells and have a protective effect on the epidermis of the large intestine.Therefore, it can be concluded that the improvement of constipation is positively correlated with the increase in SCFAs.M15 relieved constipation symptoms by increasing the levels of SCFAs in PRO mice.Serum levels of gastrointestinal regulatory-related neurotransmitters are closely related to intestinal peristalsis.MTL, GAS, and SP are excitatory regulatory peptides, and increased levels of these peptides promote promote intestinal water and electrolyte transport, regulate gastrointestinal movement, accelerate GI time, and relieve constipation, whereas, SS, ET-1, and VIP are inhibitory regulatory peptides, and decreased levels of these peptides in the serum relax the sphincter and play an important role in cardiovascular, neuroendocrine and other aspects 14 .MTL influences the transport of water and electrolytes, promotes gastric contractions and small intestine segmental movement, accelerates intestinal transfer time, and increases colon movement.Gas stimulates the secretion of gastric acid and pepsinogen and promotes the growth of digestive tract mucosa, the contraction of the GI smooth muscle, and the relaxation of the pyloric sphincter.SP adjusts the contraction of the GI tract, intestinal motility, and gastric acid secretion.VIP is a polypeptide composed of 28 amino acids whose function is to relax the GI tract and GI sphincter, and it significantly promotes the colon cancer induced by carcinogens in mice.VIP is an important factor in the production of descending inhibition, resulting in slow transmission 16 .The combined action of excitatory and inhibitory regulatory peptides accelerates intestinal emptying.In the present study, the CON group showed obvious constipation-related symptoms, including a significant decrease in MTL, Gas, and SP levels, and an increase in ET-1, SS, and VIP levels, but M15 increased serum levels of MTL, GAS and SP in CON mice (P < 0.05, Fig. 3).This suggested that M15 may reduce the severity of constipation by modulating neuropeptide levels.
Recently, the change in intestinal microbiome composition has been closely associated with the pathophysiology of constipation 7,17 .Notably, there are many reports that probiotics not only benefit the health of the intestinal tract but also regulate the intestinal flora of the host 18 .Therefore, in this study, we studied the effect of M15 on the intestinal flora of CON mice to explore the specific mechanisms through which M15 relieved constipation symptoms in CON mice.Alpha diversity is used to analyze the richness of gut microbiota.Here, we evaluated microbial community diversity using the Shannon index at the OTU level.The regulatory effect of M15 on microbial diversity in CON mice is shown in Fig. 5. Notably, M15 partially restored intestinal bacterial diversity in CON mice.It has been reported that alpha diversity of fecal flora is related to fecal water concentration.A study showed that with the decrease in fecal moisture, community diversity decreased and reached the lowest value among individuals with diarrhea 19 .The water content of PHE was greater than that of PRO in this study (Figs. 1, 2), while the results from Shannon's index showed that the community diversity of the PHE group was higher than that of the PRO and CON groups (Fig. 5), which was in agreement with the results of previous reports.. Fu et al. 20 performed 16S rDNA sequencing of the fecal samples from constipated patients and found that the abundance and diversity of intestinal flora were significantly lower in constipated patients than in healthy people.The abundances of Firmicutes and Bacteroidetes have been used as determinants of human constipation 21 .At the phylum level, for humans and mice, the overall composition of microbiota in feces is mainly dominated by Firmicutes and Bacteroidetes.Many studies have shown that constipation is associated with changes in the gut microbiota.On the one hand, the activity of gut microbes can promote intestinal motility by influencing the concentration of SCFAs.It has been reported that LAB in the intestine can change intestinal motility through SCFAs, accelerating stool formation, promoting defecation, and reducing constipation symptoms 22 .SCFAs are absorbed and can reduce the osmotic pressure of intestinal cells.Such intestinal cells hold enough water and do not absorb more water from the stool to be excreted (Fig. 3).Bacteroidetes can produce propionic acid, and butyric acid levels are positively correlated with the relative abundance of Firmicutes.Both propionic acid and butyric acid levels play an important role in relieving constipation.On the other hand, the abundance of Bacteroides and Firmicutes can improve intestinal motility by provoking the release of 5-HT or by promoting cholinergic pathways.Similarly, in our study (Fig. 7), compared with the NOR group, the proportion of Firmicutes increased in the CON group, while the number of Sclerotinia, Verrucosa and Proteus decreased.Sclerotinia, Verrucosa and Proteus have been associated with colitis and gastroenteritis, and these species of anaerobes are pathogenic to humans.Overall,the contents of intestinal metabolites are closely related to the composition of intestinal flora.
Wang et al. 11 found that the number of bifidobacteria and lactobacillus in the feces of constipated patients was significantly lower than that in healthy people.According to species composition analysis at the genus level, we found significant differences between the PHE and PRO groups; Lactobacilli were increased, while Akkemansia were decreased in the PRO group, indicating that phenolphthalein and probiotics had different regulatory effects on the intestinal flora of model CON mice.Additionally, Lactobacillus has been reported to suppress inflammation and promote gastrointestinal motility, improving constipation 23 .The associated underlying mechanisms of Lactobacillus species ameliorating constipation symptoms are likely through the increase in fecal softness, stool shaping, and defecation frequency 24 .The increase in lactobacillus in the PRO group suggested that M15 had a positive effect against constipation in mice.The β diversity analysis is mainly used to study species diversity among different samples and can be represented by a PCoA diagram (Fig. 8).We found differences between the intestinal flora compositions of the NOR and CON groups, and the PHE and PRO groups, but the intestinal flora compositions of the NOR and PRO groups were closely similar.This indicated that administration of M15 improved the intestinal flora of CON mice to a certain extent alleviating the damaging effect of sucralfate.

Conclusion
This study will provide the following valuable data for clinical practice: (1) in the treatment of constipation, M15 has a similar effect as phenolphthalein in improving intestinal peristalsis and increasing fecal moisture content; (2) M15 and phenolphthalein can regulate intestinal flora structure and increase fecal SCFA content; however, compared with phenolphthalein, M15 have different effects on the structure of gut microbiota and the composition of SCFAs in feces.In conclusion, we demonstrated that M15 improved intestinal emptying and modulated gut bacterial populations, thereby alleviating constipation in CON mice.M15 supplementation in CON mice improved fecal water content, intestinal peristalsis, and modulated gut flora and regulatory peptides.The potential therapeutic mechanism of M15 is related to the recovery of intestinal microbial composition, as well as the beneficial regulatory effects of intestinal metabolites such as SCFA.But the specific regulatory substances and regulatory pathways need more research.In all, M15 can be a potential probiotic strategy against constipation.

Chemicals and reagents
2 mg/5 ml sucralfate (Haipu Pharmaceutical, China) was diluted twice in 0.8% normal saline.The solution of activated carbon powder was prepared as follows: 100 g of Arabic gum was boiled in 800 ml of water until the solution turned transparent.Then, the solution was added with 50 g of activated carbon and boiled for another 30 min.Next, the mixture was cooled, diluted to 1000 ml with water, and then stored at 4 °C.The solution was thoroughly mixed before use.The kit for measuring serum neuropeptide levels was purchased from Lewin Bioengineering Institute, Shanghai, China.De Man, Rogosa, and Sharpe agar (MRS) culture medium were from Beijing Luqiao Technology Co., Ltd, China.All the used reagents were of analytical grade.

Strain and culture condition
M15 was isolated from breast milk, which from locally recruited individuals and informed consent was obtained.M15 was preserved in China Center for Type Culture Collection (Wuhan, China) with the preservation number CCTCC M 2021904.M15 stored in glycerol MRS broth (30% (v/v), − 80 °C) was first cultured in MRS media under the anaerobic condition at 37 °C for 24-48 h and then transferred to fresh MRS media at 2% (v/v) inoculum.M15 needs to be activated at least three times continuously.For the animal experiments, the M15 bacterial suspension was prepared in sterile normal saline at 1 × 10 9 CFU/ml.

M15 tolerance test against artificial gastric and intestinal juices
Probiotics should not only survive against the gastric and intestinal juices but also be able to colonize the gut.Accordingly, we tested the survival of M15 against the artificial gastric and intestinal juices as follows.Briefly, the M15 solution was centrifuged for 10 min at 5000 rpm and 4 °C.The obtained supernatant was discarded and the bacterial pellet was suspended in normal saline (10 9 colony-forming units, CFU/ml). 1 ml of M15 suspension was added to 50 ml of artificial gastric juice (pH 3.0) and after incubation for 3 h at 37 °C, the viable bacteria were counted to find the M15 tolerance.For the tolerance test against the intestinal juice, after the 3 h incubation with the artificial gastric juice from the first step, 1 mL of artificial gastric juice (having M15) was mixed with 24 ml of artificial intestinal juice and the mixture was incubated at 37 °C for 3 h.Afterward, the number of viable bacteria was counted using the GB 4789.35-2016code.

Determination of M15 adhesion properties
The adhesion of M15 to Caco-2 (Purchased from North Carolina Bio Corporation) cells was detected according to the method of Coconnier et al. 25 .Briefly, a slide was placed in a six-well plate, then added with 1 ml of cell fluid (2 × 10 5 cells/well) for culture for 24 h.Then, the slide was washed with sterile normal saline to remove unattached Caco-2 cells. 1 ml of the strain suspension (5 × 10 7 CFU/ml) was added into the well and incubated in a CO 2 room at 37 °C for 2 h.The unattached bacteria were removed by washing with sterile normal saline.Finally, the slide was fixed in methanol (Aladdin) and examined under a microscope after Gram staining.

Animal trial
Animals and experiment design Twenty-four female specific-pathogens-free BALB/c mice (age 6-8 weeks, weight 18-22 g) were randomly divided into four groups and kept under adaptive feeding for one week before the experiment (room temperature, 25 ± 2 °C; relative humidity, 50 ± 5%; 12 h light/12 h dark cycle).All mice were fed the usual diet from day 1 to the end of the study (Day 21).The normal group (NOR) was given 1 ml saline solution by intragastric administration until the end of the study (Day 21).To establish the mice constipation model, mice were gavaged 1 ml of sucralfate (50%) in saline solution (Day 7).The constipation model was validated based on the constipation symptoms such as the volume reduction and dryness/hardness of the fecal stools 8,26 .Eighteen constipated mice were divided into three treatment groups (6 each): the constipation group was treated with 0.8% sterilized saline (CON; 1 ml), the probiotic group was treated with M15 suspension (PRO; 1 ml × 10 9 CFU/ml), and the phenolphthalein group was treated with 1 ml phenolphthalein (PHE; 70 mg/kg body weight).Howarth and Sullivan 27 found that polyphenols can dredge constipation.Therefore, the polyphenol treatment group was used as a control experiment.All groups were treated with the corresponding dosage once a day via oral gavage for 2 weeks until the end of the study (Day 21).Mice in each group were maintained in single cages.The feces of mice on the 7th, 14th, and 21st days were collected and frozen to detect the content of organic acids in the feces.At the conclusion of the study period, all mice were anesthetised with 4% isoflurane and sacrificed by cervical dislocation.

Figure 2 .
Figure 2. (A) M15 improved intestinal propulsive rate in constipated mice.The activated carbon propulsion rate in normal (NOR) constipation (CON), phenolphthalein (PHE), and probiotic (PRO:M15) groups.# p < 0.05 compared with NOR; *p < 0.05 compared with CON; and **p < 0.05 compared with PRO.(B) M15 improved intestinal transit length in constipated mice.Active carbon propulsion in normal (NOR) constipation (CON), phenolphthalein (PHE), and probiotic (PRO:M15) groups.The red arrows indicate the peristalsis distance of activated carbon in the small intestines of corresponding mice.

Figure 4 .
Figure 4. M15 supplementation alleviated constipation-induced pathological implications of the small intestine.Intestinal tissue sections were observed at ×100 using a light microscope.Arrow marks show inflammatory infiltrations.NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.

Figure 5 .
Figure 5.The difference in α diversity index of fecal samples in respective mice.NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.

Figure 6 .
Figure 6.Relative community composition analysis in fecal samples of respective mice at the phylum level.NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.

Figure 7 .
Figure 7.The histogram of community composition analysis in fecal samples at the genus level.NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.

Figure 8 .
Figure 8. Principal coordinates analysis (PCoA) plot based on unweighted UniFrac metric.Each colored symbol represents the composition of the fecal microbiota in one mouse.NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.

Table 1 .
Comparison of SCFA content in stool of mice in each group.Results are expressed as the means ± SD (n = 6).NOR normal group, CON constipation group, PHE phenolphthalein treatment group, PRO probiotic treatment group.a p < 0.05 compared with NOR.b p < 0.05 compared with CON.c p < 0.05 compared with PHE.d p < 0.05 compared with PRO.